Influence of climatic factors on tree growth in riparian forests in the humid and dry savannas of the Volta basin,Ghana

Key message

The paper demonstrates the prospects and applications of dendrochronology for understanding climate change effects on riparian forests in the savanna landscape. 

Abstract

Riparian trees in savannas have a potential for dendro-climatic studies, but have been neglected hitherto. We examined ring-width series of Afzelia africana (evergreen) and Anogeissus leiocarpus (deciduous) to study the influence of climatic factors on the growth of riparian trees in the humid (HS) and dry (DS) savanna zones of the Volta basin in Ghana. A total of 31 stem discs belonging to A. africana and A. leiocarpus were selected from HS and DS to establish species-specific local chronologies of tree growth. Each individual of A. africana and A. leiocarpus from the two savanna sites showed distinct growth rings. Cross-dating of individual tree-ring patterns was successful using standard dendrochronological techniques. The mean annual growth rates of A. africana in the HS (1.38 ± 0.09) and DS (1.34 ± 0.08) were not statistically different. Furthermore, mean annual growth rate of A. leiocarpus in the DS (3.75 ± 0.27) was higher than in the HS (2.83 ± 0.16) suggesting that species in drier environment can have higher growth rates when sufficient soil moisture is available. The growth rates of both species at the same sites were different, which might indicate different water use strategies. High correlations of individual tree-ring series of A. africana and A. leiocarpus trees at HS and DS suggest a strong climatic forcing controlled by the seasonal movement of the inter-tropical convergence zone. The annual growth of A. africana and A. leiocarpus at both the HS and DS was significantly correlated with local temperature and precipitation. The negative correlations of the growth of the two tree species to global sea surface temperatures were however, indications that the growth of riparian forests can be impacted during El Niño-Southern Oscillation years. The result of our study shows that riparian trees in the humid and dry savanna zones of West Africa can be successfully used for dendrochronological studies.

     

Therapeutic DNA Vaccination of Vertically HIV-Infected Children: Report of the First Pediatric Randomised Trial (PEDVAC)

Subjects

Twenty vertically HIV-infected children, 6–16 years of age, with stable viral load control and CD4+ values above 400 cells/mm³.

Intervention

Ten subjects continued their ongoing antiretroviral treatment (ART, Group A) and 10 were immunized with a HIV-DNA vaccine in addition to their previous therapy (ART and vaccine, Group B). The genetic vaccine represented HIV-1 subtypes A, B and C, encoded Env, Rev, Gag and RT and had no additional adjuvant. Immunizations took place at weeks 0, 4 and 12, with a boosting dose at week 36. Monitoring was performed until week 60 and extended to week 96.

Results

Safety data showed good tolerance of the vaccine. Adherence to ART remained high and persistent during the study and did not differ significantly between controls and vaccinees. Neither group experienced either virological failure or a decline of CD4+ counts from baseline. Higher HIV-specific cellular immune responses were noted transiently to Gag but not to other components of the vaccine. Lymphoproliferative responses to a virion antigen HIV-1 MN were higher in the vaccinees than in the controls (p = 0.047), whereas differences in reactivity to clade-specific Gag p24, RT or Env did not reach significance. Compared to baseline, the percentage of HIV-specific CD8+ lymphocytes releasing perforin in the Group B was higher after the vaccination schedule had been completed (p = 0.031). No increased CD8+ perforin levels were observed in control Group A.

Conclusions

The present study demonstrates the feasibility, safety and moderate immunogenicity of genetic vaccination in vertically HIV-infected children, paving the way for amplified immunotherapeutic approaches in the pediatric population.

Trial registration

clinicaltrialsregister.eu _2007-002359-18 IT     

Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults

BackgroundThis Phase IV study evaluated the safety and immunogenicity of a two-dose, MF59^®-adjuvanted (Novartis Vaccines, Marburg, Germany), monovalent, A/H1N1 pandemic influenza vaccination schedule in Human Immunodeficiency Virus (HIV) positive children and young adults.MethodsA total of 83 children infected with HIV-1, and 37 non-immunocompromised, age-matched controls were enrolled. All participants received two vaccine doses administered three weeks apart. Antibody responses were assessed by haemagglutination assay at baseline, three weeks after each vaccine dose, and six months after immunization. Vaccines were evaluated according to European influenza vaccine licensure criteria.ResultsThe investigational vaccine was well tolerated. After the first vaccine dose, seroconversion rates were significantly lower in HIV-positive patients (60%) than controls (82%), with GMTs of 419 and 600, respectively. No significant differences in seroconversion rates were observed between the two study groups in response to the second vaccine dose. Persisting antibody titers were similar for both HIV-positive and non-infected controls, six months after immunization.ConclusionOne dose of MF59-adjuvanted vaccine was sufficient to provide adequate levels of seroprotection against A/H1N1 influenza disease in HIV-positive children. However, a two-dose vaccination schedule may be optimal for this population.     

Development of an Electronic Medical Record Based Alert for Risk of HIV Treatment Failure in a Low-Resource Setting

Background

The adoption of electronic medical record systems in resource-limited settings can help clinicians monitor patients'' adherence to HIV antiretroviral therapy (ART) and identify patients at risk of future ART failure, allowing resources to be targeted to those most at risk.

Methods

Among adult patients enrolled on ART from 2005–2013 at two large, public-sector hospitals in Haiti, ART failure was assessed after 6–12 months on treatment, based on the World Health Organization''s immunologic and clinical criteria. We identified models for predicting ART failure based on ART adherence measures and other patient characteristics. We assessed performance of candidate models using area under the receiver operating curve, and validated results using a randomly-split data sample. The selected prediction model was used to generate a risk score, and its ability to differentiate ART failure risk over a 42-month follow-up period was tested using stratified Kaplan Meier survival curves.

Results

Among 923 patients with CD4 results available during the period 6–12 months after ART initiation, 196 (21.2%) met ART failure criteria. The pharmacy-based proportion of days covered (PDC) measure performed best among five possible ART adherence measures at predicting ART failure. Average PDC during the first 6 months on ART was 79.0% among cases of ART failure and 88.6% among cases of non-failure (p<0.01). When additional information including sex, baseline CD4, and duration of enrollment in HIV care prior to ART initiation were added to PDC, the risk score differentiated between those who did and did not meet failure criteria over 42 months following ART initiation.

Conclusions

Pharmacy data are most useful for new ART adherence alerts within iSanté. Such alerts offer potential to help clinicians identify patients at high risk of ART failure so that they can be targeted with adherence support interventions, before ART failure occurs.